Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Anixa Biosciences Inc (ANIX)

Anixa Biosciences Inc (ANIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 88,849
  • Shares Outstanding, K 33,528
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,930 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 0.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.68

Options Overview Details

View History
  • Implied Volatility 212.37% (+6.33%)
  • Historical Volatility 40.80%
  • IV Percentile 43%
  • IV Rank 17.89%
  • IV High 822.56% on 01/02/26
  • IV Low 79.42% on 05/29/25
  • Expected Move (DTE 27) 0.68 (25.66%)
  • Put/Call Vol Ratio 68.33
  • Today's Volume 1,248
  • Volume Avg (30-Day) 348
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 3,536
  • Open Int (30-Day) 2,811
  • Expected Range 1.97 to 3.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/26
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.10
  • Prior Year -0.09
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.63 +0.76%
on 03/20/26
3.05 -13.11%
on 03/09/26
-0.23 (-7.99%)
since 02/20/26
3-Month
2.63 +0.76%
on 03/20/26
3.58 -25.98%
on 01/09/26
-0.65 (-19.70%)
since 12/19/25
52-Week
2.33 +13.69%
on 04/08/25
5.46 -51.43%
on 12/09/25
-0.50 (-15.87%)
since 03/20/25

Most Recent Stories

More News
Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast

SAN JOSE, Calif. , March 12, 2026 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 2.65 (-4.33%)
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platform

ANIX : 2.65 (-4.33%)
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data

ANIX : 2.65 (-4.33%)
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology

ANIX : 2.65 (-4.33%)
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

Multiple patients substantially exceed expected survival at low dose levels; absence of dose- limiting toxicities supports escalation to doses up to 100x higher

ANIX : 2.65 (-4.33%)
Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

SAN JOSE, Calif. , Feb. 2, 2026 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 2.65 (-4.33%)
Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology

Notice of Allowance marks first Mexican patent to be issued on Anixa Breast Cancer Vaccine

ANIX : 2.65 (-4.33%)
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

SAN JOSE, Calif. , Dec. 15, 2025 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 2.65 (-4.33%)
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose

ANIX : 2.65 (-4.33%)
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025

SAN JOSE, Calif. , Dec. 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 2.65 (-4.33%)

Business Summary

Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.

See More

Key Turning Points

3rd Resistance Point 3.08
2nd Resistance Point 2.98
1st Resistance Point 2.82
Last Price 2.65
1st Support Level 2.56
2nd Support Level 2.46
3rd Support Level 2.30

See More

52-Week High 5.46
Fibonacci 61.8% 4.26
Fibonacci 50% 3.89
Fibonacci 38.2% 3.52
Last Price 2.65
52-Week Low 2.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.